S&P 500   5,052.45 (-0.19%)
DOW   37,806.91 (+0.19%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
S&P 500   5,052.45 (-0.19%)
DOW   37,806.91 (+0.19%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
S&P 500   5,052.45 (-0.19%)
DOW   37,806.91 (+0.19%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
S&P 500   5,052.45 (-0.19%)
DOW   37,806.91 (+0.19%)
QQQ   430.55 (-0.12%)
AAPL   168.68 (-2.32%)
MSFT   415.54 (+0.46%)
META   500.71 (+0.10%)
GOOGL   154.27 (-0.38%)
AMZN   183.23 (-0.21%)
TSLA   155.87 (-3.47%)
NVDA   871.06 (+1.28%)
AMD   162.55 (+1.39%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.00 (-1.48%)
F   12.13 (-0.82%)
MU   120.71 (-0.54%)
GE   155.63 (+1.26%)
CGC   6.73 (-3.58%)
DIS   113.85 (+0.80%)
AMC   2.76 (+11.74%)
PFE   25.80 (-0.42%)
PYPL   63.66 (+0.24%)
XOM   118.23 (-1.21%)
NASDAQ:CEMI

Chembio Diagnostics (CEMI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.45
$0.46
50-Day Range
$0.33
$0.46
52-Week Range
$0.19
$1.24
Volume
351,642 shs
Average Volume
661,416 shs
Market Capitalization
$16.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CEMI stock logo

About Chembio Diagnostics Stock (NASDAQ:CEMI)

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

CEMI Stock News Headlines

Quest Diagnostics Inc DGX
Top 5 AI Stocks to Buy for 2024
5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.
Top 5 AI Stocks to Buy for 2024
5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.
Chembio’s CEO Letter to Stockholders
CEMI Chembio Diagnostics, Inc.
Chembio Diagnostics
See More Headlines
Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CEMI
Employees
337
Year Founded
N/A

Profitability

Net Income
$-23,290,000.00
Pretax Margin
-46.96%

Debt

Sales & Book Value

Annual Sales
$48.34 million
Book Value
$0.48 per share

Miscellaneous

Free Float
35,514,000
Market Cap
$16.71 million
Optionable
Not Optionable
Beta
1.85
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

CEMI Stock Analysis - Frequently Asked Questions

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) released its earnings results on Thursday, November, 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.05. The business had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 113.57% and a negative net margin of 47.03%. During the same quarter last year, the firm earned ($0.28) EPS.

What other stocks do shareholders of Chembio Diagnostics own?
This page (NASDAQ:CEMI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners